Table 3.
Risk analysis of pneumonitis and pneumonia of different ICIs in different tumoral types.
| NSCLC RR, 95%CI (%) | Other tumoral types RR, 95%CI (%) | |||||||
|---|---|---|---|---|---|---|---|---|
| Pneumonitis (G1-5) | Pneumonitis (G3-5) | Pneumonia (G1-5) | Pneumonia (G3-5) | Pneumonitis (G1-5) | Pneumonitis (G3-5) | Pneumonia (G1-5) | Pneumonia (G3-5) | |
| PD-L1 vs. Control | 3.25 (1.61–6.57)* |
2.16 (0.65–7.20) |
NA | NA | NA | NA | 2.11 (1.20–3.70)* | 1.13 (0.48–2.65) |
| PD−1 vs. Chemo | 4.93 (2.35–10.34)* | 4.19 (1.50–11.76)* | 0.70 (0.31–1.59) | 0.43 (0.20–0.93)* | 5.69 (2.00–16.24)* | 4.05 (1.04–15.78)* | 4.87 (0.62–38.50) | 1.01 (0.49–2.08) |
| CTLA4 vs. Control | NA | NA | NA | NA | 6.37 (0.80–50.66) | 3.32 (0.55–20.09) | 1.68 (0.61–4.64) | 2.15 (0.50–9.27) |
NSCLC, non-small cell lung cancer; Others, including MM, HNSCC, Prostate cancer, and Mesothelioma; Chemo, chemotherapy; NA, not available; RR, risk ratio; 95%CI, 95% confidence interval.
*
p < 0.05.